If the association between a disease and the HLA system is strong only relatively small numbers of patients and controls are necessary to confirm it, but when the association is weak, problems of sampling and statistical errors assume greater importance. These have been reviewed, and so far none of the reported associations between HLA antigens and asbestosis have achieved significance when the probability value has been multiplied by the total number of antigens tested. Ignoring the trend may, however, obscure the association, and further data should be obtained.
HLA-B12 was found in 18 of our 37 (49°,) patients with asbestosis. This antigen was also found in 16 out of 20 (80"%)
patients with cryptogenic fibrosing alveolitis 8-a disorder similar to asbestosis but without the history of occupational exposure -and in four out of eight children with the highly pathogenic strain of Haemophilus influenza serotype B. 9 If HLA-B112 does increase susceptibility to the damaging effects of asbestos on the lung and to the development of cryptogenic fibrosing alveolitis, this would imply that in the HLA region of chromosome 6 in man a pulmonary fibrogenic gene is in linkage disequilibrium with HLA-B12. Since the external agent in asbestosis is known it may prove possible to elucidate further the pathogenesis of asbestosis and the significance of the interaction of the HLA antigens with environmental precipitating factors in general.
The high prevalence of HLA-BW5 (tables II-V) in exposed workers without asbestosis and with clear radiographs raises the possibility that possession of this antigen may protect against the development of pulmonary fibrosis. This is not an entirely new concept since it has been shown that progressive massive fibrosis (PMF) occurs in a low percentage of coalminers1 0 with HLA-BW18. Moreover, patients with carcinoma of the bronchus survive longer after pneumonectomy'1 if they are positive for HLA-BWl9 and B5.
When exploring HLA associations with disease, studies of families offer confirmation of the findings,'2 but it is unlikely that this will be possible in asbestos workers, who, unlike coalminers and cotton workers, do not traditionally follow relatives into similar work. If further studies of HLA antigens are made in this disorder we cannot emphasise too strongly the need for applying rigid criteria for the diagnosis. ' 
Summary
In a case of quinine-induced agranulocytosis marrow culture studies confirmed the inhibitory effect on the patient's cells of equivalent therapeutic plasma concentrations of quinine. Similar concentrations had no effect on normal marrow cells. Quinidine, the stereoisomer of quinine, had no effect on either cells from the patient or normal cells. The results encourage the use of in-vitro bone marrow cultures for identifying drugs responsible for agranulocytosis.
Introduction Drug-induced agranulocytosis is a rare but potentially serious clinical problem, and in most cases the clinician can attempt to identify the causative agent only from the history and response to withdrawal. This is relatively simple with single-drug exposure but much more difficult, if not impossible, when several drugs have been used. Methods for identifying the causative agent in vitro are clearly desirable. We described a case of amodiaquine-induced agranulocytosis in which amodiaquine suppressed the in-vitro growth of marrow cells from the patient but not from a normal control. ' Since then a few other reports have appeared in which drugs known to have caused agranulocytosis have been tested against cultures of normal marrow cells but not against cells from patients with a suspected adverse reaction to the drug.2-4 Quinine is a documented but rare cause of agranulocytosis.5 We report a case in which it was proved in vitro to be the responsible agent.
Clinical history
A 64-year-old man with a five-year history of peripheral neuropathy and leg cramps was admitted to hospital for investigation. He had gross motor-sensory peripheral neuropathy, which was confirmed by nerve conduction studies, but extensive investigations failed to disclose a cause.
On admission oral quinine sulphate 300 mg at night was given for the leg cramps. Three days later a routine blood count showed profound neutropenia. Quinine was stopped but dextropropoxyphene with paracetamol (Di-Gesic, Dista), as needed for analgesia, and nitrazepam, which had been started on admission, were continued. The neutrophil count rapidly recovered (fig 1) and no other adverse haematological effects were noted. Bone marrow aspirations were performed six and 21 days after stopping quinine. The aspirates were morphologically normal and were used for culture studies. plasma concentration of 1 82 1tg/ml (P <0001 for days 9 and 24) and at one-tenth that concentration (P <00001 for day 9; 002 P 0 01 for day 24), whereas the controls showed no inhibition at these levels ( fig 2) . 
Discussion
The in-vitro findings in this case support the clinical suspicion that quinine was responsible for the agranulocytosis and that the reaction was idiosyncratic, since pronounced toxic effects occurred with concentrations that had no effect on normal marrow. The failure to find any inhibition with quinidine, the D-rotatory stereoisomer of quinine, was particularly interesting and pointed to a high specificity in the toxic mechanism. Since most episodes of drug-induced agranulocytosis result from idiosyncrasy, it is hardly surprising that toxicity at concentrations equivalent to therapeutic plasma levels or less was seen only with cells from the patient. In such cases, testing drugs against normal marrow cultures alone is not likely to yield much useful information.
Most workers agree that the cell that gives rise to colonies in the agar colony system is equivalent to the granulopoietic stem cell. 8 The formation of colonies, however, requires the activatton of this cell and the serial proliferation of its progeny, and we cannot distinguish from our data whether quinine had a toxic effect on either or both of these mechanisms.
Our results encourage the further use of the marrow culture system for trying to identify in vitro drugs responsible tor agranulocytosis in particular patients. At present only watersoluble drugs can be tested, which will remain a problem until non-toxic solvents for insoluble drugs are developed. A further obvious but none the less important precaution is not to test parenteral preparations containing preservatives, which are well known to be inhibitory in the marrow culture system.
Introduction
Gastrointestinal surgery is associated with a high incidence of postoperative sepsis due to contamination of the field of operation by organisms from the intestine. An incidence of serious sepsis in excess of 50",, is common. 14 Although the value of preoperative mechanical emptying of the bowel is not disputed, the use of prophylactic antibiotics in the preparation of patients for elective bowel surgery has remained controversial.5-10 Most studies of antibiotic prophylaxis have been concerned with control of infections due to aerobic bacteria, against which even prolonged courses of -systemic antibiotics have frequently proved ineffective. Clearly the rational use of prophylactic antibiotics in colonic surgery requires an understanding of the bacterial flora encountered during-surgery and of the sensitivity of the bacteria to various antibiotics.
There has been an increasing awareness of the importance of non-sporing anaerobes as a major cause of sepsis after surgery of the gastrointestinal tract.7 11-13 Indeed, recent studies13-15 which made use of the specific bactericidal activity of metronidazole against anaerobes in the prevention of postoperative sepsis after gastrointestinal and gynaecological surgery, strongly supported the view that aerobic bacteria are usually of only secondary importance in these clinical settings.
We report here the clinical and bacteriological findings of a double-blind trial of the value of metronidazole in the prophylaxis and treatment of sepsis after colonic surgery.
Patients and methods
All patients admitted to the Luton and Dunstable Hospital for elective colonic surgery during a 9-month period were admitted to the trial, provided that there was no recent history of antibiotic or metronidazole treatment. The study was a double-blind trial using active and placebo suppositories and oral tablets. Patients were randomly allocated to metronidazole and placebo groups.
Initially 64 patients were admitted to the study; 35 received prophylactic metronidazole and 29 were controls. During the study period 18 patients ceased to qualify for the trial-no colonic surgery was undertaken in seven, other antibiotic treatment was begun in eight, and the double-blind prophylaxis was incomplete in three patients. We therefore analysed 46 patients, 27 of whom received metronidazole (table I) . Most operations were for malignant disease
